Dr. Brar on the Rise of New Treatment Approaches in HCC

November 16, 2020
Gagandeep Brar, MD
Gagandeep Brar, MD

Partner | Cancer Centers | <b>Weill Cornell Sandra & Edward Meyer Cancer Center</b>

Gagandeep Brar, MD, discusses the rise of new treatment approaches in hepatocellular carcinoma.

Gagandeep Brar, MD, assistant professor of medicine, Division of Hematologic and Medical Oncology, Weill Cornell Medicine, discusses the rise of new treatment approaches in hepatocellular carcinoma (HCC).

Prior to 2017, HCC was a challenging ​disease to treat, and ​patients had fairly dismal prognos​es, Brar says.

However, over the past 3 years, a host of new data and research ​efforts have emerged, Brar adds.

Notably, in light of new treatment options, patients with HCC are now experiencing prolonged survival and improved quality of life​, explains Brar.

Ultimately, ​these developments have been encouraging in HCC and additional efforts are underway to further advance the paradigm, Brar concludes.


x